{"id":"W3158473853","doi":"10.1093/rheumatology/keab247.190","title":"P195 Efficacy of ixekizumab versus adalimumab in psoriatic arthritis (PsA) patients with and without moderate-to-severe psoriasis: 52-week results from a multicentre, randomised open-label study","year":2021,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adalimumab; Ixekizumab; Psoriatic arthritis; Clinical endpoint; Internal medicine; Post-hoc analysis; Concomitant; Psoriasis; Placebo; Randomized controlled trial; Arthritis; Rheumatoid arthritis; Secukinumab; Dermatology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004212462,0.001541808,0.003399868,0.0004048049,0.0003976867,0.001196683,0.0009735326,0.001569403,0.005142313],"category_scores_gemma":[0.002516069,0.00083039,0.00319859,0.0004082489,0.001082383,0.001060606,0.0005682146,0.002326719,0.0008660557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006910803,"about_ca_system_score_gemma":0.001015148,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006157588,"about_ca_topic_score_gemma":0.001225765,"domain_scores_codex":[0.9982271,0.001018719,0.0001468227,0.000280149,0.0001681984,0.0001591131],"domain_scores_gemma":[0.998105,0.0005558261,0.0004638342,0.0001990984,0.0001192315,0.0005569871],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9766189,0.009266091,0.001165679,0.0003393496,0.0009987536,0.00002305355,0.00004597958,0.0001698632,0.003203812,0.00003051486,0.0003063892,0.007831562],"study_design_scores_gemma":[0.7996956,0.191356,0.006896186,0.00002318766,0.000825047,0.00002756156,0.000025879,0.0003692199,0.0004027268,0.00006385177,0.0002973743,0.00001718611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945404,0.001987108,0.000367832,0.0002055261,0.0001900217,0.001364825,0.0006668599,0.00004883322,0.0006286512],"genre_scores_gemma":[0.9944002,0.0008519355,0.0008308452,0.0004695361,0.0003768442,0.00121425,0.0007682409,0.00001396142,0.001074054],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005142313,"threshold_uncertainty_score":0.02227795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02716080082459136,"score_gpt":0.2612139658328715,"score_spread":0.2340531650082802,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}